Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

Inclusion Criteria: * Patients with stage IIIB/IV non-small cell lung cancer * Patients with uncommon epidermal growth factor receptor (EGFR) mutation * Targeted-therapy-naive patients * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 * Evaluable target lesions according to RECIST 1.1 for tumour response assessment Exclusion Criteria: * Wild-type EGFR * Positive 19 del and/or 21 L858R mutation * Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib * Patients who have documented history of interstitial lung disease